N-Acetyl Semax Amidate 10 mg vial price

Not approved anywhere. The FDA evaluated plain semax in 2026 for the list of bulk substances pharmacies may compound from, for cerebral ischemia, migraine and trigeminal neuralgia, and its reviewers concluded that the criteria weigh against adding semax free base or semax acetate. The same document records that semax is a registered drug in Russia, available as 0.1 percent and 1 percent nasal drops, and that no human pharmacokinetic study of it could be found. What happened next is on the Semax page: as of October 28, 2026, Appendix B of the announced HHS section 503A policy covers semax free base for intranasal use, and that policy puts injectable semax and modified analogues outside it. HHS states that it "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician" when all policy conditions are met. That is interim, nonbinding enforcement discretion under a policy described as draft in the notice, not FDA approval or final placement on the 503A bulks list. This capped version is a modified analogue, and it is sold labeled for laboratory research only.